Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-LILRB4 CAR-T Therapy in Relapsed/Refractory AML
ChiCTR2200056409Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-LILRB4 CAR T cells in acute myeloid leukemia (AML), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Overall response rate (ORR), Progression-free survival (PFS) and 2 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
anti-LILRB4 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200056409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056409.